Discontinuation Rates Tolerability Profile
ORTHO TRI-CYCLEN® LO demonstrates low rates of discontinuation

  • A well-tolerated combination: 25 mcg of ethinyl estradiol and norgestimate
  • Low overall discontinuation rate of 4% due to adverse events1
    • –  Less than 0.1% discontinuation (1 out of 1723 patients)
          due to weight gain2,3
    • –  Less than 1% due to bleeding irregularities*2
*Includes bleeding between menstrual periods, withdrawal bleeding, menstrual disorder,    uterine hemorrhage, menorrhagia, and vaginal hemorrhage.
    References:
  1. Hampton RM, Short M, Bieber E, et al. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. Contraception. 2001;63:289-295.
  2. Data on file, Ortho-McNeil-Janssen Pharmaceuticals, Inc.
  3. Burkman R, LaGuardia K, Fisher A, Wu S-C, Creasy G. An assessment of
    ORTHO TRI-CYCLEN® LO on body weight and study discontinuation. Poster presented at: 51st Annual Clinical Meeting of the American College of Obstetricians and Gynecologists; April 26-30, 2003; New Orleans, LA.
ORTHO TRI-CYCLEN® LO demonstrates an excellent tolerability profile

    References:
  1. Hampton RM, Short M, Bieber E, et al. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. Contraception. 2001;63:289-295.
  2. Data on file, Ortho-McNeil-Janssen Pharmaceuticals, Inc.